Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 13,266 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Adult Disease Clear all

Conditions: Asthma
Interventions: FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 12 Years and older
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 21
States / cities: Scottsdale, Arizona • Tempe, Arizona • Encinitas, California + 18 more

Conditions: Healthy
Interventions: Avenanthramide-enriched oats; Other
Lead sponsor: Tufts University; Other
Eligibility: 50 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19, SARS-CoV-2 Infection
Interventions: NVX-Cov2373; Drug
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 911 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 30
States / cities: Long Beach, California • Sacramento, California • DeLand, Florida + 26 more

Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: selumetinib, cetuximab, laboratory biomarker analysis, pharmacological study; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Bethesda, Maryland • Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Type 2 Diabetes, Cardiovascular Disease
Interventions: TAK-875, TAK-875 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 3,207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 218
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 215 more

Conditions: Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions: Efinopegdutide, Semaglutide, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 42
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more

Conditions: Postoperative Cognitive Complications, Delirium, Perioperative/Postoperative Complications, Brain Injuries, Anesthesia
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Growth Hormone Deficiency
Interventions: TV-1106, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 25
States / cities: Artesia, California • Fountain Valley, California • Miami, Florida + 15 more

Conditions: Lymphoma
Interventions: filgrastim, carmustine, cyclophosphamide, cytarabine, dexamethasone, etoposide, mitoxantrone hydrochloride, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Delirium, Dementia
Interventions: Speed of Processing Training, Internet-Based Contact Control; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 65 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Generalized Anxiety Disorder (GAD), Healthy Participants
Interventions: ABBV-932, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Human Immunodeficiency Virus
Interventions: Busulfan, Cal-1 modified HSPC, Cal-1 modified CD4+ T lymphocytes; Drug · Biological
Lead sponsor: Calimmune, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions: DASH Diet, Usual diet; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 60 Years to 74 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Obstructive Sleep Apnea
Interventions: Genio™ system; Device
Lead sponsor: Nyxoah S.A.; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 16
States / cities: Birmingham, Alabama • Boca Raton, Florida • Tampa, Florida + 12 more

Conditions: Health Adult Subjects, Obesity & Overweight
Interventions: TIX100, Placebo; Drug
Lead sponsor: TIXiMED, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Leukemia
Interventions: Alemtuzumab, Etoposide, Dexamethasone, Methotrexate, Phone Call, Tocilizumab; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes
Interventions: High intensity aerobic interval training, Continuous moderate intensity exercise; Other
Lead sponsor: University of Florida; Other
Eligibility: 30 Years to 79 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Liver Transplant, Hepatitis C
Interventions: Cyclosporine A, Tacrolimus; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Mechanical Ventilation Complication, Complementary Health Approach
Interventions: Reiki therapy, Sham Reiki; Other
Lead sponsor: Ohio State University; Other
Eligibility: 55 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Coronavirus Disease 2019 (COVID-19)
Interventions: AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]); Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Modesto, California • Westminster, California + 13 more

Conditions: Substance Use Disorders, Posttraumatic Stress Symptom, Anxiety
Interventions: Safe and Sound Protocol; Device
Lead sponsor: Caron Treatment Centers; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Wernersville, Pennsylvania

Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, PIK3CA Mutation, HER2- Negative Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor, Cervical Cancer
Interventions: RGT-490; Drug
Lead sponsor: Regor Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Pittsburgh, Pennsylvania • Houston, Texas + 2 more

Conditions: Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations, AML, Leukemia
Interventions: Revumenib, Midostaurin, Cytarabine, Daunorubicin; Drug
Lead sponsor: Richard Stone, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: New Haven, Connecticut • Boston, Massachusetts

Conditions: Infectious Disease
Interventions: Start Antibiotics / Continue Antibiotics for treatment of bacteriuria, No Antibiotics for treatment of bacteriuria; Drug · Other
Lead sponsor: Mount Sinai Hospital, Canada; Other
Eligibility: 60 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults

Bioavailability of Avenanthramide-Enriched Oats in Healthy Older Adults

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

Prospective Observational Multimodal Neuromonitoring During High-Risk Adult Surgery

Study of TV-1106 in Growth Hormone-Deficient Adults

Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

Speed of Processing Training for Cognitive Deficits After Delirium in Older Adults

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

Randomized Controlled Pilot Trial of DASH Feeding in Older Low Socioeconomic Adults Without Heart Failure

Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea (DREAM)

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

Effect of Aerobic Interval Training on Cardiovascular Function in Type 2 Diabetes

Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus

Reiki Intervention for Seriously Ill Elders Intensive Care Unit (RISE-ICU)

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19

Safe & Sound Protocol in Adults With Trauma and SUD

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Revumenib in Combination With 7+3 + Midostaurin in AML

Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection